Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Askling

Showing results (51-60 of 345) with videos related to

Pageof 35
Sort By:
Arthritis Research & Therapy|June 20, 2014
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort studyLotta Ljung, Johan Askling, Solbritt Rantapää-Dahlqvist, et al.
Annals of the Rheumatic Diseases|March 13, 2020
Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factorsHjalmar Wadström, Andreas Pettersson, Karin E Smedby, et al.
Arthritis Research & Therapy|August 11, 2018
Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control studyKari Johansson, Johan Askling, Lars Alfredsson, et al.
Annals of the Rheumatic Diseases|June 29, 2012
Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based studyElizabeth V Arkema, Ronald F van Vollenhoven, Johan Askling, et al.
Annals of the Rheumatic Diseases|December 11, 2013
Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?Jonas K Eriksson, Kari Johansson, Johan Askling, et al.
BMC Musculoskeletal Disorders|December 17, 2014
Validation of the rheumatoid arthritis diagnosis in the Swedish National Patient Register: a cohort study from Stockholm CountyKristin Waldenlind, Jonas K Eriksson, Bernhard Grewin, et al.
RMD Open|March 16, 2026
Can alternative means of phenotyping rheumatoid arthritis reduce its apparent heterogeneity? A comparison of three disease activity classifications with DAS28Simon Steiger, Helga Westerlind, Daniela Di Giuseppe, et al.
Arthritis and Rheumatism|February 10, 2011
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agentsPauline Raaschou, Julia F Simard, Martin Neovius, et al.
International Journal of Cancer|May 18, 2004
Maternal breast cancer risk after the death of a childMats Lambe, Ruha Cerrato, Johan Askling, et al.
BMJ (Clinical Research Ed.)|April 10, 2013
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from SwedenPauline Raaschou, Julia F Simard, Marie Holmqvist, et al.
Pageof 35

Showing results (51-60 of 345) with videos related to

Sort By:
Pageof 35
Arthritis Research & Therapy|June 20, 2014
The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort studyLotta Ljung, Johan Askling, Solbritt Rantapää-Dahlqvist, et al.
Annals of the Rheumatic Diseases|March 13, 2020
Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factorsHjalmar Wadström, Andreas Pettersson, Karin E Smedby, et al.
Arthritis Research & Therapy|August 11, 2018
Mediterranean diet and risk of rheumatoid arthritis: a population-based case-control studyKari Johansson, Johan Askling, Lars Alfredsson, et al.
Annals of the Rheumatic Diseases|June 29, 2012
Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based studyElizabeth V Arkema, Ronald F van Vollenhoven, Johan Askling, et al.
Annals of the Rheumatic Diseases|December 11, 2013
Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?Jonas K Eriksson, Kari Johansson, Johan Askling, et al.
BMC Musculoskeletal Disorders|December 17, 2014
Validation of the rheumatoid arthritis diagnosis in the Swedish National Patient Register: a cohort study from Stockholm CountyKristin Waldenlind, Jonas K Eriksson, Bernhard Grewin, et al.
RMD Open|March 16, 2026
Can alternative means of phenotyping rheumatoid arthritis reduce its apparent heterogeneity? A comparison of three disease activity classifications with DAS28Simon Steiger, Helga Westerlind, Daniela Di Giuseppe, et al.
Arthritis and Rheumatism|February 10, 2011
Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agentsPauline Raaschou, Julia F Simard, Martin Neovius, et al.
International Journal of Cancer|May 18, 2004
Maternal breast cancer risk after the death of a childMats Lambe, Ruha Cerrato, Johan Askling, et al.
BMJ (Clinical Research Ed.)|April 10, 2013
Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from SwedenPauline Raaschou, Julia F Simard, Marie Holmqvist, et al.
Pageof 35